# Faeth Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2024

- Company: [Faeth Therapeutics, Inc.](/companies/fth.md) (CIK 1829802)
- Form: 10-Q
- Filed: 2024-08-06
- Accepted by EDGAR: Aug 6, 2024, 16:30 ET
- Period: 2024-06-30
- Accession: 0000950170-24-091895
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1829802/000095017024091895/snse-20240630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1829802/000095017024091895/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 3 months, 2024-04-01 to 2024-06-30 | −$7.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2024-01-01 to 2024-06-30 | −$16.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2024-04-01 to 2024-06-30 | $24.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2024-01-01 to 2024-06-30 | $52.0k | us-gaap:InterestExpense |
| Income tax | 6 months, 2024-01-01 to 2024-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-04-01 to 2024-06-30 | −$7.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2024-01-01 to 2024-06-30 | −$15.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-04-01 to 2024-06-30 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2024-01-01 to 2024-06-30 | −$0.60 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-04-01 to 2024-06-30 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2024-01-01 to 2024-06-30 | −$0.60 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-04-01 to 2024-06-30 | 25,104,439 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2024-01-01 to 2024-06-30 | 25,076,775 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2024-01-01 to 2024-06-30 | −$13.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2024-01-01 to 2024-06-30 | $146.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-06-30 | $11.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-06-30 | $53.9m | us-gaap:AssetsCurrent |
| Total assets | at 2024-06-30 | $59.8m | us-gaap:Assets |
| Current liabilities | at 2024-06-30 | $4.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-06-30 | $7.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2024-06-30 | $52.2m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1829802/000095017024091895/snse-20240630.htm

Filed Aug 6, 2024.
Source: SEC EDGAR, the filing index for accession 0000950170-24-091895. Last ingested by Listed: Nov 3, 2026, 23:17 ET. No prices; not investment advice.